Business Context and Reporting Period
This Form 8-K Current Report was filed by Viking Therapeutics, Inc. on February 6, 2018. The filing reports the closing of a previously announced underwritten public offering of the Company's common stock.
Key Financial Metrics
The filing details the following transaction metrics regarding the equity offering:
- Shares Sold: 12,650,000 shares of common stock.
- Offering Price: $5.00 per share.
- Over-Allotment: Included 1,650,000 shares sold pursuant to the underwriters' full exercise of their option to cover over-allotments.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for total gross proceeds, net proceeds, or the Company's operating revenue, profit, or cash flow positions.
- Debt and Liquidity: The filing text does not provide a clear value for outstanding debt or current liquidity ratios.
Material Changes
The primary material change reported is the increase in the Company's outstanding share count and capitalization resulting from the closing of the public offering. No comparative financial period data is provided in this specific filing to assess changes in operating performance.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not contain specific management commentary, forward-looking guidance, or a detailed discussion of risks and contingencies within the body of the 8-K text provided. The document confirms the Company is an emerging growth company.
Investor Verification Checklist
- Verify the total gross proceeds and net proceeds after underwriting discounts and commissions by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the updated total number of shares outstanding post-offering.
- Review the Company's most recent 10-K or 10-Q for current cash balances and burn rate to assess the impact of the new capital on runway.
- Check for any lock-up agreements or restrictions on the newly issued shares.